Concerto HealthAI signs on with Pfizer to apply real-world data to precision cancer medicine

Pfizer sign
The project plans to identify patient populations for combination therapy trials and conduct real-world outcomes studies with the first results expected in early 2020. (Photo: Tracy Staton)

Concerto HealthAI has inked its second real-world data collaboration with a Big Pharma company in as many weeks, this time to help Pfizer select patients for its precision oncology development work.

Concerto, a SymphonyAI company, aims to design more efficient clinical trials using prefabricated control arms and data from electronic medical records and insurance claims, as well as economic outcome measures, all through the use of artificial intelligence and machine learning.

In late March, the company signed on to a multi-year project with Bristol-Myers Squibb focusing on a range of different cancers. At Pfizer, Concerto’s work will cover investigational and approved treatments, across both solid and blood tumors.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Bristol-Myers Squibb taps Concerto HealthAI for real-world cancer data work and trial design

The project will also look to identify new patient subpopulations for combination cancer therapy trials, according to a statement from Concerto CEO Jeff Elton, and includes plans to design and conduct real-world outcomes studies using synthetic control arms, with the first results expected early next year.

In addition to other sources, Concerto’s eurekaHealth platform incorporates data under license from the American Society of Clinical Oncology’s CancerLinQ program, a quality monitoring system that collects patient encounter data. Through a separate collaboration with ASCO, the FDA and the tech firm Tempus, Concerto is also working to broaden the use of real-world evidence in pre- and post-approval studies.

Concerto and Tempus, a molecular data repository builder, are currently working with the FDA analyze de-identified CancerLinQ data covering more than 10,000 patients treated with immune system checkpoint inhibitors.

RELATED: Pfizer links 15 genome sites to depression by digging into 23andMe data

Pfizer, meanwhile, has been exploring the use of real-world data through a number of partnerships, including with BC Platforms in cardiovascular disease, the cloud-based TriNetX global clinical research network, and IBM for the development of remote patient monitoring sensors.

Suggested Articles

The FDA disclosed over 60 safety reports related to intra-aortic balloon pumps manufactured by Maquet and Datascope, following a recall this summer.

Truvian Sciences raised $27.1 million to fuel the development of its benchtop blood tester, bringing the company’s total funding to $46.3 million.

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.